Wan Q, et al. – Aim was to assess the effectiveness and safety of 0.1% tacrolimus eye drop in the tarsal form of vernal keratoconjunctivitis (VKC) and to survey the changes of dendritic cells at the palpebral conjunctiva in patients with VKC by in vivo confocal microscopy. Tacrolimus 0.1% eye drops are a successful and safe treatment for the tarsal form of VKC, and can rapidly inhibit the activity of dendritic cells, improve symptoms, decrease papillary hyperplasia, and reverse damage at the palpebral conjunctiva. The side effects could influence the compliance of some patients.